Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02844179 · ClinicalTrials.gov registry record · Phase 1
(+)-Alpha-Dihydrotetrabenazine Phase I
A Phase 1 study of Healthy Subjects, sponsored by Kirk A. Frey.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT02844179 is a Phase 1 study of Healthy Subjects that has completed, run by Kirk A. Frey. The registered enrollment target is 6 participants, below the 129-participant average among 69 other Healthy Subjects trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02844179, a Phase 1 study of Healthy Subjects, has completed, sponsored by Kirk A. Frey.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is intended to determine the initial safety and tolerability of single oral doses of the drug (+)-alpha-dihydrotetrabenaxine (HTBZ) in normal volunteers. HTBZ is believed to be the active ingredient in the FDA-approved drug tetrabenazine (TBZ, brand name Xenazine), prescribed for treatment of involuntary movements in patients with Huntington's chorea. TBZ is a mixture of closely-related compounds (isomers) and is readily metabolized (converted) in the human body to HTBZ and related isomers. Investigators believe that HTBZ, the drug to be studied in this research, is the active ingredient in TBZ. The present study will confirm safety and tolerability of HTBZ and will investigate its expected effects on brain sites that are the target of TBZ therapy.
Conditions Studied
Interventions
- DRUG HTBZ
Study Locations (1)
Michigan
- University of Michigan hospitals - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2016-07 |
| Est. Completion | 2017-06-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02844179
The ClinicalTrials.gov registry entry for NCT02844179 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 129-participant average among 69 other Healthy Subjects trials with a reported enrollment target (95% lower). The listed sponsor is Kirk A. Frey, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Subjects appearing as the primary indexed condition, and to 1 intervention - of which HTBZ is the first listed.
NCT02844179 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT02844179 about?
NCT02844179 is a clinical study titled "(+)-Alpha-Dihydrotetrabenazine Phase I". This research study is intended to determine the initial safety and tolerability of single oral doses of the drug (+)-alpha-dihydrotetrabenaxine (HTBZ) in normal volunteers. HTBZ is believed to be the active ingredient in the FDA-approved drug tetrabenazine (TBZ, brand name Xenazine), prescribed for...
What is the current status of trial NCT02844179?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2016-07. Estimated completion is 2017-06-27.
What conditions does trial NCT02844179 study?
This clinical trial studies the following conditions: Healthy Subjects.
What interventions are being tested in trial NCT02844179?
The interventions under investigation include: HTBZ (DRUG).
Who is sponsoring clinical trial NCT02844179?
This trial is sponsored by Kirk A. Frey, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02844179 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Subjects
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I Study of ICP-332 in Healthy Subjects
RECRUITING · Phase 1
-
A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects
RECRUITING · Phase 1
-
Phase 1 Study of Intravaginal KB15A
RECRUITING · Phase 1
-
A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations
COMPLETED · Phase 1
-
Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol®
COMPLETED · Phase 1
-
A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.